- Home
- CSTL vs REAL Comparison
CSTL vs REAL Comparison
Compare CSTL & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- REAL
- Stock Information
- Founded
- CSTL 2007
- REAL 2011
- Country
- CSTL United States
- REAL United States
- Employees
- CSTL N/A
- REAL N/A
- Industry
- CSTL Medical Specialities
- REAL Other Specialty Stores
- Sector
- CSTL Health Care
- REAL Consumer Discretionary
- Exchange
- CSTL Nasdaq
- REAL Nasdaq
- Market Cap
- CSTL 558.7M
- REAL 641.9M
- IPO Year
- CSTL 2019
- REAL 2019
- Fundamental
- Price
- CSTL $16.75
- REAL $5.48
- Analyst Decision
- CSTL Strong Buy
- REAL Buy
- Analyst Count
- CSTL 6
- REAL 5
- Target Price
- CSTL $38.33
- REAL $8.40
- AVG Volume (30 Days)
- CSTL 548.5K
- REAL 4.0M
- Earning Date
- CSTL 05-05-2025
- REAL 05-08-2025
- Dividend Yield
- CSTL N/A
- REAL N/A
- EPS Growth
- CSTL N/A
- REAL N/A
- EPS
- CSTL N/A
- REAL N/A
- Revenue
- CSTL $347,083,000.00
- REAL $616,717,000.00
- Revenue This Year
- CSTL N/A
- REAL $11.35
- Revenue Next Year
- CSTL $1.80
- REAL $9.35
- P/E Ratio
- CSTL N/A
- REAL N/A
- Revenue Growth
- CSTL 38.43
- REAL 11.89
- 52 Week Low
- CSTL $15.70
- REAL $2.24
- 52 Week High
- CSTL $35.84
- REAL $11.38
- Technical
- Relative Strength Index (RSI)
- CSTL 34.74
- REAL 45.93
- Support Level
- CSTL $15.84
- REAL $5.18
- Resistance Level
- CSTL $17.49
- REAL $5.97
- Average True Range (ATR)
- CSTL 0.90
- REAL 0.47
- MACD
- CSTL -0.18
- REAL -0.10
- Stochastic Oscillator
- CSTL 22.73
- REAL 23.70
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.